镥[177Lu] 特昔维匹肽(Lutetium (177 Lu) Vipivotide Tetraxetan) - 药物靶点：PSMA_在研适应症：转移性前列腺癌，PSMA阳性去势抵抗性前列腺癌，激素依赖性前列腺癌_专利_临床

概要

基本信息

药物类型

多肽偶联核素、治疗用放射药物

别名

177-Lutetium-PSMA-617(RadioMedix, Inc.)、[Lu-177] vipivotide tetraxetan、Lu-177-PSMA-617 Lutetium-177-PSMA-617

+ [16]

靶点

PSMA

作用方式

抑制剂

作用机制

PSMA抑制剂(前列腺癌特异性膜抗原抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病消化系统疾病+ [2]

在研适应症

转移性前列腺癌PSMA阳性去势抵抗性前列腺癌激素依赖性前列腺癌+ [15]

非在研适应症-

原研机构

RadioMedix, Inc.

在研机构

Novartis Pharma AG

Novartis Pharmaceuticals Corp.Advanced Accelerator Applications (Italy) Srl

+ [13]

非在研机构

Novartis Europharm Ltd.

权益机构

中国同辐股份有限公司

Endocyte, Inc.

原子高科股份有限公司

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2022-03-23),

PSMA阳性去势抵抗性前列腺癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、孤儿药 (韩国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C49H68LuN9O16

InChIKeyRSTDSVVLNYFDHY-NLQOEHMXSA-K

CAS号1703749-62-5

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

97

项与镥[177Lu] 特昔维匹肽相关的临床试验

NCT07698535

/ Not yet recruiting临床2期IIT

Dynamic Assessments of Molecular Response to Guide Early 177Lu-PSMA-617 Treatment Discontinuation: The DYNAMO Study

This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.

开始日期2026-12-01

申办/合作机构

University of Washington

[+1]

NCT07682649

/ Not yet recruiting临床1期IIT

A Phase 1 Study to Investigate Safety of Escalating Cycle 1 Dose of Lu-177-PSMA-617 Radioligand Therapy (RLT) in Metastatic Castration Resistant Prostate Cancer (mCRPC): The ESCENDO Trial

This phase I trial studies the safety, side effects, and treatment cycle 1 best dose of Lu-177-PSMA-617 in patients with prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castration-resistant) and has spread from where it first started (primary site) to other places in the body (metastatic). Lu-177-PSMA-617 is a radioactive drug. It binds to a protein called prostate-specific membrane antigen (PSMA), which is found on prostate cancer tumor cells. Lu-177-PSMA-617 gives off radiation that may kill these tumor cells. It is a type of radioconjugate. Lu-177-PSMA-617 is currently used in a series of 6 intravenous infusions of the standard dosage, each separated by 6 weeks from the previous infusion. Investigators have observed that the first therapy administration (cycle 1) delivers better radiation treatment to the cancer than each of the following 5 infusions. Giving an increased dosage of Lu-177-PSMA-617 in treatment cycle 1 may have a better effect on metastatic castration-resistant prostate cancer than the standard dosage. The study does not change the total cumulative activity from what is used in the standard dosage treatment but gives an increased dosage in cycle 1 and reduces the total number of cycles.

开始日期2026-08-01

申办/合作机构

Rogel Cancer Center: University of Michigan

[+1]

NCT07677566

/ Not yet recruiting临床4期IIT

177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial

The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy. The main questions it aims to answer are:
Does this combination treatment improve the pathological complete response rate (pCR)? What is the minimal residual disease (MRD) rate in these patients? What are the safety profiles and any adverse effects associated with this treatment? Researchers will compare the combination of darolutamide and 177Lu-PSMA-617 to a placebo to see if the combination is effective in treating high-risk localized prostate cancer.
Participants will:
Receive either darolutamide combined with 177Lu-PSMA-617 or a placebo every day for 12 weeks.
Visit the clinic every 6 weeks for checkups and tests. Keep a diary of their symptoms and any side effects experienced during the treatment.
Undergo imaging tests, including prostate MRI and PSMA PET/CT, before surgery and during follow-up.

开始日期2026-07-01

申办/合作机构

Bayer AG

100 项与镥[177Lu] 特昔维匹肽相关的临床结果

登录后查看更多信息

100 项与镥[177Lu] 特昔维匹肽相关的转化医学

登录后查看更多信息

100 项与镥[177Lu] 特昔维匹肽相关的专利（医药）

登录后查看更多信息

738

项与镥[177Lu] 特昔维匹肽相关的文献（医药）

2026-08-01·APPLIED RADIATION AND ISOTOPES

Preclinical assessment of 177Lu-DOTA-Pip-Nle-CycMSHhex: In vivo evaluation and human dosimetry estimation

Article

作者: Shirmardi, Seyed Pezhman ; Alirezapour, Behrouz ; Zolghadri, Samaneh ; Erfani, Mostafa ; Yousefnia, Hassan ; Karimian, Arezou

This study presents a preclinical assessment of ¹⁷⁷Lu-DOTA-Pip-Nle-CycMSHhex (¹⁷⁷Lu-CCZ01048), a previously reported radiolabeled α-MSH analogue targeting melanoma, with a focus on additional in vivo evaluation and human dosimetry extrapolation. ¹⁷⁷Lu-CCZ01048 was radiolabeled with a radiochemical purity exceeding 99% and demonstrated high stability in phosphate-buffered saline (PBS) and human serum, consistent with previous reports. Receptor binding assays confirmed a high affinity for the melanocortin-1 receptor (MC1R), with a dissociation constant (K_d) of 0.51 ± 0.09 nM, while internalization studies showed more than 50% cellular uptake in B16F10 melanoma cells within 6 h. Cytotoxicity evaluation using the MTT assay revealed a significant reduction in cell viability, with a 31% decrease observed at a concentration of 1000 nM. Biodistribution studies in tumor-bearing mice demonstrated high tumor uptake, rapid blood clearance, and minimal accumulation in non-target organs, accompanied by predominant renal metabolism and excretion. SPECT imaging confirmed selective tumor targeting. Absorbed dose estimates based on tumor-bearing mice biodistribution data identified the kidneys as the dose-limiting organ, while overall dosimetry values were within the range reported for clinically used and FDA-approved ¹⁷⁷Lu-labeled radiopharmaceuticals, including ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-PSMA-617. These findings support further preclinical and translational evaluation of ¹⁷⁷Lu-CCZ01048 for melanoma-targeted radionuclide therapy.

2026-08-01·CLINICAL NUCLEAR MEDICINE

PSMA Expression Heterogeneity in Metastatic Prostate Carcinoma: A Case of Discordant Liver Metastases on 68Ga PSMA PET/CT Showing Uptake on Post–Lu-177 PSMA Therapy Scan

Article

作者: Kumar, Rakesh ; Jain, Bela ; Baberwal, Parth ; Khandelwal, Yogita

We report a case of metastatic castration-resistant prostate carcinoma with discordant PSMA (prostate specific membrane antigen) expression— 68 Ga-PSMA PET/CT (positron emission tomography/computed tomography) showed PSMA-avid skeletal metastases but nonavid liver lesions. The patient received 177 Lu-PSMA-617 on compassionate grounds. Post-therapy imaging revealed radiotracer uptake in both skeletal and previously nonavid hepatic metastases, suggesting possible increased lesion amenability. This case highlights the dynamic nature of PSMA expression and the potential role of post-therapy scans in revealing responsive disease not visualized on baseline imaging.

2026-08-01·CLINICAL NUCLEAR MEDICINE

Imaging Discordance Between [⁶⁸Ga]-PSMA PET and [¹⁷⁷Lu]-PSMA SPECT in mCRPC

Article

作者: Tuncel, Murat ; Ergün, Eser Lay ; Uğur, Ömer ; Küçüker, Cansu ; Kaya, Gürsan

PSMA PET/CT is commonly used for selecting candidates for [¹⁷⁷Lu]-PSMA radioligand therapy (LuPSMA RLT). However, discrepancies may occur due to pharmacokinetic and biodistribution differences between [⁶⁸Ga]-PSMA-11 and [¹⁷⁷Lu]-PSMA-617 ligands. Such discordance risks underestimating disease burden and excluding eligible patients. We present a case of metastatic castration-resistant prostate cancer (mCRPC) in whom a PSMA-negative adrenal lesion on PET exhibited significant LuPSMA uptake post-therapy and was subsequently confirmed as FDG-avid. Complementary stereotactic body radiotherapy (SBRT) achieved metabolic remission. This case highlights the clinical significance of integrating post-therapy LuPSMA imaging and FDG PET/CT with systemic treatment to ensure accurate disease characterization and personalized management of PSMA−/FDG+ lesions in advanced prostate cancer.

1,835

项与镥[177Lu] 特昔维匹肽相关的新闻（医药）

2026-08-04

·癌度

《癌度快报》2026年8月4日：8 月 FDA 将审评 3 款肿瘤创新药：溶瘤病毒、多发性骨髓瘤新药、放射性配体疗法！

一、新药快讯 1、8 月 FDA 将审评 3 款肿瘤创新药：溶瘤病毒、多发性骨髓瘤新药、放射性配体疗法！预计 2026 年 8 月，美国 FDA 将对 3 款肿瘤创新药做出审批决定。RP1（vusolimogene oderparepvec）是 Replimune 开发的溶瘤病毒免疫疗法，基于单纯疱疹病毒改造，表达融合蛋白 GALV-GP R-和 GM-CSF，与 PD-1 抑制剂 nivolumab 联用治疗晚期黑色素瘤。1/2 期 IGNYTE 试验显示，总缓解率（ORR）32.9%，中位缓解持续时间 21.6 个月，PDUFA 目标日期 8 月 2 日。Iberdomide是百时美施贵宝开发的口服 cereblon E3 连接酶调节剂（CELMoD），联合 daratumumab 和地塞米松治疗复发或难治性多发性骨髓瘤，若获批将成为首款 CELMoD 药物，PDUFA 目标日期 8 月 17 日。177Lu-edotreotide（ITM-11）是 ITM 公司开发的放射性配体疗法，靶向生长抑素受体，治疗不可手术切除的胃肠胰神经内分泌肿瘤（GEP-NET），由生长抑素类似物 edotreotide 与镥 -177 偶联而成。 2、诺华 Pluvicto 联合疗法获 FDA 批准，前列腺癌疾病进展风险降低 33%! 诺华放射性配体疗法 Pluvicto（镥 -177）获 FDA 批准联合雄激素受体通路抑制剂（ARPI），治疗 PSMA（前列腺特异性膜抗原）阳性的转移性激素敏感性前列腺癌（mHSPC）。基于 PSMAddition 3 期试验，Pluvicto 联合标准治疗将疾病进展或死亡风险降低 33%（HR=0.67），总生存期（OS）也呈现获益趋势（HR=0.80）。Pluvicto 是静脉给药的放射性配体疗法（RLT），靶向结合表达 PSMA 的前列腺癌细胞，释放辐射能量损伤靶细胞。此次批准使 Pluvicto 可用于前列腺癌各疾病阶段，符合条件的患者人群规模接近翻倍。 3、礼来 KRAS G12C 抑制剂 olomorasib 获 FDA 突破性疗法认定，用于晚期胰腺癌！礼来公司下一代 KRAS G12C 抑制剂 olomorasib 获 FDA 突破性疗法认定，用于单药治疗既往至少接受过一种系统性治疗的 KRAS G12C 突变晚期胰腺癌患者。基于 1/2 期 LOXO-RAS-20001 研究的初步结果，olomorasib 是口服、强效且高选择性的在研抑制剂，药代动力学特性支持较高的预测靶点占有率，单药或联合用药均具有较高效力。此前，olomorasib 联合 K 药（pembrolizumab）已获突破性疗法认定，用于一线治疗 KRAS G12C 突变且 PD-L1 表达≥50% 的晚期非小细胞肺癌患者。二、抗癌前沿 1、《科学》子刊：改造双歧杆菌定点释放 IL-2，胰腺癌肿瘤生长显著抑制！《科学 - 进展》杂志发表一项胰腺癌治疗新策略：研究人员改造双歧杆菌（一种安全益生菌），使其在肿瘤内部定点、持续释放白介素 -2（IL-2）。双歧杆菌是厌氧菌，会选择性定植于缺氧的肿瘤组织，不在正常器官存活。改造后的工程菌株"BifidoSumIL-2"插入编码 IL-2 的基因，并对 IL-2 进行额外设计以增强对效应 T 细胞的结合力。小鼠实验显示，BifidoSumIL-2 显著增加肿瘤内效应 T 细胞数量，降低耗竭 T 细胞和调节性 T 细胞比例，肿瘤生长受到明显抑制。与标准化疗、局部放疗及抗 PD-L1 免疫检查点抑制剂联合应用，三联疗法的肿瘤抑制效果和生存期延长均显著优于任何单一疗法。该策略为胰腺癌等免疫抑制肿瘤的治疗提供了潜在新方向。 👉 点击文末【阅读原文】；或关注公众号后点菜单栏“联系我们”；或微信直接扫描下图二维码；我们协助您申请适合您的临床试验！点赞收藏分享点亮小手爱心，送来温暖鼓励

突破性疗法临床3期临床结果免疫疗法快速通道

2026-08-04

·Firstwordpharma

Novartis' Pluvicto gets US nod for hormone-sensitive prostate cancer

US regulators announced Friday that Novartis' Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved for patients with PSMA-positive, metastatic hormone-sensitive prostate cancer (mHSPC), significantly expanding the number of patients eligible for the radioligand therapy.The approval extends Pluvicto's use beyond metastatic castration-resistant prostate cancer. "The treatment landscape for mHSPC is evolving, and this approval reflects a growing recognition that earlier treatment intensification matters," said Michael Morris, a principal investigator of the pivotal PSMAddition study in the US.In the trial, Pluvicto combined with standard of care – an androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) – reduced the risk of disease progression or death by 28% versus standard therapy alone at the primary analysis. Updated findings showed the benefit widening to a 33% reduction, according to Novartis, with overall survival (OS) trending in Pluvicto's favour with a 0.80 hazard ratio, though data remain immature.Safety results were consistent with those from the VISION and PSMAfore studies, which supported Pluvicto's approvals in 2022 and 2025 in castration-resistant prostate cancer. At primary analysis, grade ≥3 adverse events (AEs) were reported in 50.7% of patients who received Pluvicto plus standard care compared to 43% for standard care alone. Doubling eligible patient poolThe company estimates more than 186,000 men are diagnosed globally with mHSPC each year, and roughly half progress to castration-resistant disease within 20 months despite ARPI-ADT doublet therapy. Novartis US president Victor Bultó said the expanded label "nearly [doubles] the number of patients who may benefit from this targeted approach."Still, despite the strength of the radiographic progression-free survival (rPFS) signal, key opinion leaders (KOLs) who spoke to FirstWord expressed caution about broad first-line adoption, citing concerns over long-term marrow toxicity, uncertainty around OS durability in a crossover-heavy trial, and high incremental cost (see – Spotlight On: Novartis' Pluvicto pushes further upstream — but HSPC use looks headed for a selective, high-burden niche).The approval comes as Novartis continues to expand its radioligand manufacturing network, with five US production sites operational or under construction to support anticipated demand.

上市批准临床结果

2026-08-03

·药明康德

诺华放射性配体疗法再获FDA批准；礼来KRAS G12C抑制剂获FDA突破性疗法认定 | 产业新闻

诺华放射性配体疗法再获FDA批准诺华（Novartis）日前宣布，美国FDA已批准Pluvicto（lutetium Lu 177 vipivotide tetraxetan）联合雄激素受体通路抑制剂（ARPI），用于治疗前列腺特异性膜抗原（PSMA）阳性的转移性雄激素通路调节初治或敏感型（mAPMN/S）前列腺癌患者，该疾病通常被称为转移性激素敏感性前列腺癌（mHSPC）。此次批准基于3期PSMAddition试验的结果。该试验显示，与单独接受标准治疗（SoC）相比，Pluvicto联合标准治疗可将疾病进展或死亡风险降低28%（HR=0.72；95% CI：0.58～0.90）。在随后更新的分析中，Pluvicto联合治疗进一步将疾病进展或死亡风险降低33%（HR=0.67；95% CI：0.55～0.82）。同时，总生存期（OS）也呈现有利于Pluvicto联合标准治疗的趋势（HR=0.80；95% CI：0.63～1.01）。 Pluvicto目前可用于PSMA阳性转移性前列腺癌的各个疾病阶段，使符合治疗条件的患者人群规模接近翻倍。 Pluvicto是一种静脉给药的放射性配体疗法（RLT），由靶向化合物（配体）与治疗性放射性核素（本产品中为镥-177）组成。进入血液循环后，Pluvicto可与靶细胞结合，其中包括表达PSMA这一跨膜蛋白的前列腺癌细胞。结合后，放射性同位素释放的能量可损伤靶细胞及其周围细胞，干扰其复制能力和/或诱导细胞死亡。礼来KRAS G12C抑制剂获FDA突破性疗法认定礼来公司（Eli Lilly and Company）今日宣布，美国FDA已授予olomorasib突破性疗法认定，用于单药治疗经FDA批准的检测确认携带KRAS G12C突变、既往至少接受过一种系统性治疗的晚期胰腺癌成人患者。Olomorasib是一款强效且具有高度选择性的在研下一代KRAS G12C抑制剂。此前，olomorasib联合抗PD-1疗法Keytruda（pembrolizumab）已获得突破性疗法认定，用于一线治疗经FDA批准的检测确认携带KRAS G12C突变且PD-L1表达≥50%的局部晚期或转移性非小细胞肺癌（NSCLC）患者。此次FDA授予突破性疗法认定，是基于开放标签、多中心1/2期LOXO-RAS-20001研究所取得的令人鼓舞的初步结果。该研究在携带KRAS G12C突变的晚期实体瘤患者中评估olomorasib，其中包括既往至少接受过一种系统性治疗的晚期胰腺癌患者。 Olomorasib是一款口服、强效且具有高度选择性的下一代KRAS G12C蛋白抑制剂。Olomorasib经过专门设计，可靶向KRAS G12C，其药代动力学特性支持较高的预测靶点占有率，并使其在单药或联合用药时均具有较高效力。参考资料： [1] Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer. Retrieved August 3, 2026, from https://www.prnewswire.com/news-releases/lillys-olomorasib-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-previously-treated-kras-g12c-mutant-advanced-pancreatic-cancer-302840337.html [2] FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease. Retrieved August 3, 2026, from https://www.globenewswire.com/news-release/2026/07/31/3337056/0/en/fda-approves-pluvicto-for-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-of-care-across-metastatic-disease.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新……

100 项与镥[177Lu] 特昔维匹肽相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性前列腺癌	美国	Novartis Pharmaceuticals Corp.	2026-07-31
PSMA阳性去势抵抗性前列腺癌	美国	Novartis Pharmaceuticals Corp.	2022-03-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
激素依赖性前列腺癌	申请上市	中国	Novartis Pharma Schweiz AG	2025-11-04
激素依赖性前列腺癌	申请上市	中国	Advanced Accelerator Applications (Italy) Srl	2025-11-04
激素依赖性前列腺癌	申请上市	中国	北京诺华制药有限公司	2025-11-04
寡转移性前列腺癌	临床3期	美国	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	中国	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	日本	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	比利时	Novartis Pharmaceuticals Corp.	2024-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2026	N/A	转移性去势抵抗性前列腺癌	158	Lutetium Lu 177 vipivotide tetraxetan	鑰築餘願觸夢鹹築繭艱(鑰蓋獵簾積鹹窪積築選) = 範壓夢窪簾窪鹽鏇鬱觸襯鹽鑰鹽範繭窪糧鏇艱 (鑰鏇範廠艱餘鹹鏇製網 ) 更多	积极	2026-05-29
				Lutetium Lu 177 vipivotide tetraxetan (without PSA flare)	鑰築餘願觸夢鹹築繭艱(鑰蓋獵簾積鹹窪積築選) = 鑰築衊蓋繭鏇窪獵鹽鹹襯鹽鑰鹽範繭窪糧鏇艱 (鑰鏇範廠艱餘鹹鏇製網 ) 更多
ASCO2026	N/A	神经内分泌前列腺癌	10	Lutetium-177-PSMA-617	遞衊衊膚衊繭醖餘選夢(糧鹹觸鏇願製築積淵淵) = 膚鹽鹽壓衊膚壓夢蓋齋膚淵襯壓壓憲積壓膚餘 (製網夢鹽窪構獵糧壓繭, 2 ~ NR) 更多	积极	2026-05-29
ASCO2026	临床2/3期	转移性去势抵抗性前列腺癌	2,526	Lu-177 PSMA-617	積製觸淵願鑰鑰觸積顧(廠顧憲膚夢餘繭齋淵顧): RR = 0.98 (95.0% CI, 0.83 ~ 1.14), P-Value = 0.75 更多	积极	2026-05-29
				standardized treatment
ASCO2026	N/A	转移性去势抵抗性前列腺癌 BRCA1 altered \| BRCA2 altered	728	177Lu-PSMA-617 (BRCA-altered)	憲醖鬱窪願膚夢鏇積襯(餘遞構糧淵願積遞構簾): HR = 2.01 (95.0% CI, 0.53 ~ 7.64), P-Value = 2.01	不佳	2026-05-29
				177Lu-PSMA-617 (Non-BRCA)
ASCO2026	临床2期	激素依赖性前列腺癌	160	Lu-PSMA	鬱觸積膚願淵窪糧膚鑰(範築製襯襯蓋獵夢繭築) = 鬱鏇繭築鹹積鏇憲願鹹憲衊艱網鏇蓋簾選艱夢 (鹹糧簾廠餘願獵願鏇選 ) 更多	积极	2026-05-29
				standard treatment	鬱觸積膚願淵窪糧膚鑰(範築製襯襯蓋獵夢繭築) = 願築鏇顧醖鬱膚築願製憲衊艱網鏇蓋簾選艱夢 (鹹糧簾廠餘願獵願鏇選 ) 更多
ASCO2026	N/A	转移性去势抵抗性前列腺癌	81	177Lu-PSMA-617 (Chemotherapy Naïve)	窪獵鹽觸簾衊艱顧鏇鬱(選糧願觸淵鏇鹽築觸襯) = fatigue (53%), dry mouth (30%), anemia (14%), nausea/vomiting (12%). 夢齋膚廠襯齋夢衊壓鬱 (壓齋觸簾鬱餘選築廠獵 ) 更多	积极	2026-05-29
				177Lu-PSMA-617 (Chemotherapy Exposed)
ASCO2026	N/A	前列腺癌	6,464	Lutetium (Lu 177 ) vipivotide tetraxetan	膚艱餘選選繭鹹網蓋膚(襯憲鏇網衊網顧鹹夢艱) = 獵壓淵遞製餘製繭淵顧艱鹹窪夢憲廠範鹽構襯 (鏇願艱鏇齋獵簾繭鬱鑰 ) 更多	积极	2026-05-29
SNMMI2026	N/A	转移性去势抵抗性前列腺癌	12	Lu177-PSMA-617 radioligand therapy (VISION PSMA PET inclusion criteria + Initial PSMA-RLT responders)	簾淵鬱淵襯觸遞鬱壓齋(憲願願鬱鹹築淵廠鹽願) = 7/12 patients (58.3%) developed grade 1 or 2 leukopenia (no grade ≥3) 壓醖壓壓蓋醖醖廠壓構 (選夢鑰築餘顧餘築窪觸 ) 更多	积极	2026-05-27
SNMMI2026	N/A	神经内分泌肿瘤 \| 转移性去势抵抗性前列腺癌	44	Pluvicto	鬱淵顧襯願鬱艱築願製(餘餘憲齋餘鹹艱繭獵廠) = 齋網壓範餘觸壓廠鬱獵遞遞構築艱繭憲構襯網 (繭糧蓋簾顧窪鏇鬱構遞 ) 更多	积极	2026-05-27
SNMMI2026	N/A	转移性去势抵抗性前列腺癌	59	Lu-177 PSMA (≥50% PSA decline)	憲蓋壓餘網夢觸壓膚鹹(鏇糧築築膚遞膚餘遞夢) = 繭淵齋願醖顧範廠鑰膚衊夢淵觸蓋淵廠顧遞繭 (蓋鹽鏇顧遞醖憲鏇艱淵 )	积极	2026-05-27
				Lu-177 PSMA (early PSA response)	憲蓋壓餘網夢觸壓膚鹹(鏇糧築築膚遞膚餘遞夢) = 衊窪觸襯築繭鹹鏇蓋願衊夢淵觸蓋淵廠顧遞繭 (蓋鹽鏇顧遞醖憲鏇艱淵 )